9 results found.

Limited Scleroderma, or Diffuse Scleroderma Clinical Trial

Gilead Sciences - Recruiting 18 years or older.
- A Non-Interventional Pilot Study Assessing Whether Lysyl Oxidase-like 2 (LOXL2) is Present in Subjects With Scleroderma.

Scleroderma, or Calcinosis Clinical Trial

Rutgers, The State University of New Jersey - Recruiting 18 years to 85 years.
- A Prospective, Observational Study of Calcinosis in a Single-Center Population With Scleroderma-Spectrum Disorders.

Graft Versus Host Disease, or Systemic Scleroderma Clinical Trial using imatinib mesylate; rituximab; questionnaire administration

Fred Hutchinson Cancer Research Center - Recruiting 2 years or older.
- A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis After Allogeneic Hematopoietic Cell Transplantation.
imatinib mesylate; rituximab; questionnaire administration

Systemic Sclerosis, Scleroderma, Interstitial Lung Disease, or Lu Clinical Trial using Cyclophosphamide; Placebo

Assistance Publique - H“pitaux de Paris - Recruiting 18 years or older.
- Intravenous Cyclophosphamide for the Treatment of Systemic Sclerosis Associated Interstitial Lung Disease.
Cyclophosphamide; Placebo

Scleroderma Clinical Trial using ARFI-SVI Ultrasound

University of Michigan - Recruiting 18 years or older.
- Acoustic Radiation Force Impulse/Shear Wave Velocity Imaging of the Skin in Scleroderma and Other Rheumatologic Diseases.
ARFI-SVI Ultrasound

Systemic Scleroderma, or Severe Systemic Sclerosis Clinical Trial using fludarabine phosphate; Mycophenolic Acid; tacrolimus; total-body irradiation; bone marrow transplantation; reduced intensity allogeneic hematopoietic stem cell transplantation; quality-of-life assessment; laboratory biomarker analysis; flow cytometry; biopsy; cyclophosphamide

Fred Hutchinson Cancer Research Center - Recruiting N/A to 70 years.
- Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Patients With Severe Systemic Sclerosis.
fludarabine phosphate; Mycophenolic Acid; tacrolimus; total-body irradiation; bone marrow transplantation; reduced intensity allogeneic hematopoietic stem cell transplantation; quality-of-life assessment; laboratory biomarker analysis; flow cytometry; biopsy; cyclophosphamide

Scleroderma Clinical Trial using Cytoxan rATG/Fludarabine regiment followed by SCT; cyclophosphamide regimen followed by SCT

Northwestern University - Recruiting 18 years to 60 years.
- Randomized Study of Different Non-myeloablative Conditioning Regimens With Hematopoietic Stem Cell Support in Patients With Scleroderma (Autologous Systemic Sclerosis Immune Suppression Trial - II ASSIST-IIb).
Cytoxan rATG/Fludarabine regiment followed by SCT; cyclophosphamide regimen followed by SCT

Scleroderma, Systemic Clinical Trial using Platelet Gel

Universit… Politecnica delle Marche - Recruiting 18 years to 80 years.
- Platelet Gel for Digital Ulcers in Patients With SSc: a Randomized Controlled Trial.
Platelet Gel

Scleroderma Clinical Trial

University Hospital, Rouen - Recruiting 18 years to 76 years.
- Genesis of Scleroderma: Role of Environmental Factors in 100 Patients With Scleroderma and 300 Healthy Controls.